Depakin syrup in management of treatment-resistant epilepsy

Depakin-syrup was given for several weeks in initial dose 300 mg/day with graded increase of the dose to 1200 mg/day to 11 patients aged 15-39 suffering from epilepsy and residual-organic affection of CNS with epileptic syndrome. A complete or partial discontinuation of the fits was achieved in 82% of the patients, primarily in those with partial and primary-generalized fits, partial fits with secondary generalization. It is concluded that depakin syrup treatment is justified in management of epilepsy, especially in the treatment-resistant cases.